ICIQ

Institut Català d'Investigació Química

Research

Research Projects

Home / Research / Phase I clinical trial of a new antifibrinolytic agent, compound CM-352, with an efficient synthesis route, aimed at controlling disabling and lethal bleeding

Phase I clinical trial of a new antifibrinolytic agent, compound CM-352, with an efficient synthesis route, aimed at controlling disabling and lethal bleeding

From: 2023 to: 2026
Reference: CPP2022-009643
Call identifier: Proyectos Colaboración Público-Privada (CPP)
Total funding: € 3.499.214,00
ICIQ funding: € 355.575,00
Principal Investigator (PI): Fernando Bravo
Project cordinator: ICIQ-CSOL

Ministerio de Ciencia e Innovación